TP53
About
Location: 17p13.1
Mappings
Biomarkers
TP53 is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| Wild type TP53 | Wild type | 1 | 2 |
| TP53 deletion | Copy Number | 5 | 7 |
| TP53 somatic variants | Somatic Variant | 5 | 7 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) HSE (1) | Wild type TP53 | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Zanubrutinib | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Acalabrutinib | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Ibrutinib | |
| EMA (1) HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Venetoclax | |
| EMA (1) HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Zanubrutinib | |
| HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Acalabrutinib | |
| HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Ibrutinib |